Effect of treatment of hypertension in the primary preventive trial, Göteborg, Sweden.
1 A treatment group comprising 635 hypertensive men (casual SBP greater than 175 or DBP greater than 115 twice) was compared with a reference group (n = 391 men; casual SBP greater than 175 or DBP greater than 115 only at screening). All men belonged to the same population sample of 7,455 men aged 47-54 yr. 2 The two groups did not differ with respect to age, smoking habits or cholesterol values, but screening BPs were higher in the treatment group. 3 During 4.3 years' follow-up there was a significantly lower total death rate in the treatment group compared with reference group. 4 There was also a strong tendency towards lower incidence of non-fatal myocardial infarction (P = 0.06). The pooled incidence of non-fatal myocardial infarction and fatal CHD was lower in the treatment group than in the reference group (P less than 0.03).
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D001627:Bethanidine / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D002561:Cerebrovascular Disorders / Q000453:epidemiology; D003327:Coronary Disease / Q000453:epidemiology; D004232:Diuretics / Q000627:therapeutic use; D004341:Drug Evaluation; D005665:Furosemide / Q000627:therapeutic use; D006801:Humans; D006830:Hydralazine / Q000627:therapeutic use; D006973:Hypertension / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000453:epidemiology; D013148:Spironolactone / Q000627:therapeutic use; D013548:Sweden
D000319:Adrenergic beta-Antagonists; D004232:Diuretics; D006830:Hydralazine; D013148:Spironolactone; D005665:Furosemide; D001627:Bethanidine